Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Early Treatment of Psoriasis: A Window Of Opportunity?
Description
The presentation discusses the significance of early treatment for psoriasis, emphasizing the importance of timely intervention for improving patient outcomes. The speaker notes that many patients with significant psoriasis have not received systemic treatment, often delaying effective management, which can severely impact their quality of life and contribute to comorbidities. Citing research and clinical experience, the speaker argues that addressing psoriasis early can potentially reduce long-term health risks, such as cardiovascular events and the development of psoriatic arthritis. The concept of a 'molecular scar' is introduced, suggesting that early treatment might alter disease dynamics, resulting in prolonged remission or a milder disease course. Highlighting the need for further studies, the speaker advocates for a paradigm shift in dermatology towards prioritizing early intervention, which could enhance both quality and quantity of life for patients suffering from psoriasis.
Conclusions
- Early treatment of psoriasis can significantly enhance the quality of life for patients.
- Undertreatment of psoriasis remains common, with many patients receiving no therapy or only topical treatments for severe disease.
- Treating psoriasis early may help to prevent the progression of associated comorbidities, such as cardiovascular disease and psoriatic arthritis.
- Systemic treatments have been shown to improve mortality rates in patients with moderate to severe psoriasis.
- Early intervention may alter the disease's long-term trajectory, potentially resulting in more durable remission and improved skin health.
- Individuals who are treated sooner tend to have a higher likelihood of achieving clear skin compared to those treated later.
- Increased awareness and screening for cardiovascular risk factors in psoriasis patients are essential, as many remain undiagnosed and untreated.
- Research supports that new treatments may facilitate faster normalization of genomic markers associated with psoriasis, leading to prolonged periods without relapse.
- The implications of these findings suggest a paradigm shift in dermatologic care, advocating for early diagnosis and treatment of psoriasis as a crucial strategy.
- Warren RB, et al. N Engl J Med 2021; 385:130-141 DOI: 10.1056/NEJMoa2102388
- Langley RG, et al. N Engl J Med 2014; 371:326-338 DOI: 10.1056/NEJMoa1314258
- Blauvelt A, et al. JAAD, VOLUME 76, ISSUE 3, P405-417, MARCH 2017
- Lebwohl M, et al. J Am Acad Dermatol. 2014;70:871.
- Kimball A, et al. J Am Acad Dermatol. 2012;67:76-85.
- Gelfand JM, et al. Arch Dermatol. 2007;143(12):1493-1499.
- Kampylafka E, et al. Arthritis Research & Therapy (2019) 21:178 https://doi.org/10.1186/s13075-019-1957-0
- Suárez-Fariñas M, et al. J Invest Dermatol. 2011 February; 131(2): 391-400. doi:10.1038/jid.2010.280.